Cognition Therapeutics CFO James O'Brien departs; Andrew Einhorn named interim CFO

COGNITION THERAPEUTICS INC

CFO James O'Brien to leave effective August 12, 2022; departure not due to any disagreement with company or auditors.
O'Brien eligible for severance: 9 months base salary and health benefits, contingent on release and restrictive covenants.
Andrew Einhorn appointed Interim CFO effective August 12, via consulting agreement with Danforth Advisors.
Einhorn previously CFO of RVL Pharmaceuticals and Edge Therapeutics; company will search for permanent CFO.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Andrew Einhorn

Interim Chief Financial Officer

CGTX · COGNITION THERAPEUTICS INC

Effective: 2022-08-12
Filed: July 27, 2022, 7:59 PM ET

the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.

Departed

James O'Brien

Chief Financial Officer

CGTX · COGNITION THERAPEUTICS INC

Effective: 2022-08-12
Successor: Andrew Einhorn
Filed: July 27, 2022, 7:59 PM ET

the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Andrew Einhorn was appointed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

James O'Brien departed as Chief Financial Officer at COGNITION THERAPEUTICS INC.

Action: departed
Role: Chief Financial Officer

Exact text from the filing

the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022

View on SEC.gov

COGNITION THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001104659-22-083183

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.